Zentalis Pharmaceuticals
ZNTL
86 hedge funds and large institutions have $54.9M invested in Zentalis Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 30 reducing their positions, and 18 closing their positions.
7% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 30
13% less funds holding
Funds holding: 99 → 86 (-13)
16.99% less ownership
Funds ownership: 73.17% → 56.18% (-17%)
31% less capital invested
Capital invested by funds: $79.7M → $54.9M (-$24.8M)
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
+$5.03M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.58M |
| 3 |
Renaissance Technologies
New York
|
+$813K |
| 4 |
Barclays
London,
United Kingdom
|
+$592K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$591K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$21.1M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.34M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.79M |
| 4 |
Morgan Stanley
New York
|
-$879K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$838K |
ZNTL Hedge Fund Activity: Q4 2025 in Review
86 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2025, worth a combined $54.9M — down 31% from $79.7M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ZNTL and 8 opened new positions — a net loss of 10 holders — while 30 trimmed existing stakes and 28 added.
The largest buyer was 5AM Venture Management, adding an estimated $5.03M. The largest seller was Matrix Capital Management Company, exiting entirely with an estimated $21.1M sold.
- 86 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2025, down from 99 in Q3 2025.
- Funds reported $54.9M of Zentalis Pharmaceuticals stock for Q4 2025, down 31% quarter-over-quarter.
- 8 funds opened new Zentalis Pharmaceuticals positions in Q4 2025 and 18 closed out, a net change of -10 holders.
- The largest Zentalis Pharmaceuticals buyer in Q4 2025 was 5AM Venture Management, an estimated $5.03M added.
- The largest Zentalis Pharmaceuticals seller in Q4 2025 was Matrix Capital Management Company, an estimated $21.1M sold.
Based on aggregated 13F filings for Q4 2025.